Ixmyelocel-T

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Osteonecrosis

Conditions

Osteonecrosis

Trial Timeline

Sep 1, 2007 → Dec 1, 2010

NCT ID

NCT00505219

About Ixmyelocel-T

Ixmyelocel-T is a phase 3 stage product being developed by Vericel for Osteonecrosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00505219. Target conditions include Osteonecrosis.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01670981	Phase 2	Completed	Feb 20, 2013	Mar 7, 2018	Ischemic Dilated Cardiomyopathy (IDCM)
NCT01483898	Phase 3	Completed	Feb 1, 2012	Mar 25, 2014	Critical Limb Ischemia
NCT01020968	Phase 2	Completed	Dec 1, 2009	Dec 5, 2013	Dilated Cardiomyopathy
NCT00765518	Phase 2	Completed	Sep 1, 2008	Sep 5, 2012	Dilated Cardiomyopathy
NCT00505219	Phase 3	Completed	Sep 1, 2007	Dec 1, 2010	Osteonecrosis

Competing Products

3 competing products in Osteonecrosis

See all competitors

Product	Company	Stage	Hype Score
Alendronate	Merck	Approved	85
Zoledronic acid	Novartis	Phase 2	52
Zoledronic Acid + Placebo	Novartis	Phase 2	52

Other Products from Vericel

Carticel (autologous cultured chondrocyte) implantationApproved

Ixmyelocel-TPhase 3

autologous cultured chondrocytes on porcine collagen membranePhase 3

MACIPhase 3